Latest news with #Blueberries
Economic Times
03-05-2025
- Health
- Economic Times
Are all fruits healthy? Hyderabad doctor names fruits to avoid for better sugar control. See if your favourite made the list.
The role of sugar in fruits Diabetic-friendly, low-sugar fruits MORE STORIES FOR YOU ✕ « Back to recommendation stories I don't want to see these stories because They are not relevant to me They disrupt the reading flow Others SUBMIT — hyderabaddoctor (@hyderabaddoctor) Fruits to enjoy in moderation Fruits are often seen as the go-to option for a healthy snack, packed with fiber, vitamins, minerals, and antioxidants. However, not all fruits are equally beneficial, especially when it comes to their impact on metabolic health. Dr. Sudhir Kumar , a Hyderabad-based doctor, emphasises that while fruits are healthy, certain varieties may not be ideal for everyone, particularly those with concerns about blood sugar contain natural sugars, mainly fructose and glucose, which are metabolized differently from refined sugars found in processed foods. The fiber in whole fruits helps slow sugar absorption, making them a healthier choice than fruit juices or sugary treats. However, fruits higher in fructose can lead to insulin resistance, fatty liver, weight gain, and increased triglycerides in some individuals. This highlights the importance of being mindful of fruit choices for optimal metabolic those monitoring blood sugar or metabolism, choosing fruits with a low glycemic index (GI) is essential. These fruits provide beneficial nutrients without spiking blood sugar levels. Some of the best low-sugar, diabetic-friendly fruits include:(Strawberries, Blueberries, Raspberries, Blackberries) – Low in sugar and high in antioxidants.– Rich in fiber and vitamin C.– High in fiber, ideal for regulating blood sugar.(Fresh, unsweetened) – Antioxidant-rich and low in sugar.– Low in sugar and packed with vitamins A and C.– Excellent for fiber and antioxidants.– High in vitamin C and fiber.– Refreshing, with vitamin C and fruits are not only nutritious but also less likely to disrupt blood sugar balance, making them ideal for those looking to maintain metabolic fruits, though not harmful, are higher in sugar and should be consumed in moderation. These include:(like raisins and dates)(even 100% juice)These fruits can lead to sugar spikes if consumed excessively, so moderation is disclaimer read, "The information here is general in nature. The type of fruits, as well as the amount of fruits that can be eaten depend on multiple factors, including any illness, body weight, physical activity, availability, etc.). Discuss with your physician and nutritionist for individual opinion."
Time of India
03-05-2025
- Health
- Time of India
Are all fruits healthy? Hyderabad doctor names fruits to avoid for better sugar control. See if your favourite made the list.
Fruits are healthy, but some impact blood sugar. Dr. Sudhir Kumar suggests low-GI fruits for those watching blood sugar. Berries, apples, and pears are good choices. Fruits like bananas and mangoes should be eaten in moderation. Excess consumption of high-sugar fruits can lead to sugar spikes. Individual needs vary based on health and activity. Tired of too many ads? Remove Ads The role of sugar in fruits Diabetic-friendly, low-sugar fruits Tired of too many ads? Remove Ads Popular in Panache Fruits to enjoy in moderation Tired of too many ads? Remove Ads Fruits are often seen as the go-to option for a healthy snack, packed with fiber, vitamins, minerals, and antioxidants. However, not all fruits are equally beneficial, especially when it comes to their impact on metabolic health. Dr. Sudhir Kumar , a Hyderabad-based doctor, emphasises that while fruits are healthy, certain varieties may not be ideal for everyone, particularly those with concerns about blood sugar contain natural sugars, mainly fructose and glucose, which are metabolized differently from refined sugars found in processed foods. The fiber in whole fruits helps slow sugar absorption, making them a healthier choice than fruit juices or sugary treats. However, fruits higher in fructose can lead to insulin resistance, fatty liver, weight gain, and increased triglycerides in some individuals. This highlights the importance of being mindful of fruit choices for optimal metabolic those monitoring blood sugar or metabolism, choosing fruits with a low glycemic index (GI) is essential. These fruits provide beneficial nutrients without spiking blood sugar levels. Some of the best low-sugar, diabetic-friendly fruits include:(Strawberries, Blueberries, Raspberries, Blackberries) – Low in sugar and high in antioxidants.– Rich in fiber and vitamin C.– High in fiber, ideal for regulating blood sugar.(Fresh, unsweetened) – Antioxidant-rich and low in sugar.– Low in sugar and packed with vitamins A and C.– Excellent for fiber and antioxidants.– High in vitamin C and fiber.– Refreshing, with vitamin C and fruits are not only nutritious but also less likely to disrupt blood sugar balance, making them ideal for those looking to maintain metabolic fruits, though not harmful, are higher in sugar and should be consumed in moderation. These include:(like raisins and dates)(even 100% juice)These fruits can lead to sugar spikes if consumed excessively, so moderation is disclaimer read, "The information here is general in nature. The type of fruits, as well as the amount of fruits that can be eaten depend on multiple factors, including any illness, body weight, physical activity, availability, etc.). Discuss with your physician and nutritionist for individual opinion."
Associated Press
25-03-2025
- Business
- Associated Press
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the 'Company' or 'Blueberries'), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares ('Common Shares') at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the 'Offering'). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2025. It is expected that the Offering will be led by Terraflos Inc. ('Terraflos'), a company with operations throughout Latin America founded and controlled by Facundo Garreton ('Mr. Garreton'), who serves as the Chairman, CEO, and a director of Blueberries. Terraflos is currently exploring various prospects in Argentina, Mexico, and Brazil and aims to expand its operations into those markets in the short term. The company's objective is to satisfy food and medicine needs in the near future using non-conventional methods, without exploiting natural resources as is common in current methodologies. In addition, Guillermo Rodriguez, a director of the Company, is also expected to participate in the Offering. Early Warning Disclosure Immediately prior to the Offering Mr. Garreton, directly and through Terraflos, owned 242,346,666 Common Shares, options exercisable into 5,049,500 Common Shares (the 'Options'). If the Options were exercised in full, it would result in the issuance of 5,049,500 Common Shares to Mr. Garreton for an aggregate holdings on an as converted basis of 247,396,166 Common Shares, representing, on a partially diluted basis, approximately 61.23% of the outstanding Common Shares prior to the Offering. Immediately following the Offering, Mr. Garreton owned on an as converted basis (assuming the exercise the Options), directly and through Terraflos: 313,461,101 Common Shares representing, on a partially diluted basis, approximately 62.67% of the outstanding Common Shares. Mr. Garreton, through Terraflos, acquired the Common Shares for investment purposes, and he may, depending on market and other conditions, increase or decrease his beneficial ownership, control or direction over additional securities of the securities or otherwise. Other than as noted above and a right to a board seat for so long as Mr. Garreton holds at least 8% of the outstanding Common Shares on an as converted basis, Mr. Garreton does not have any plans related to any of the matters in the enumerated list in Item 5.1 of Form 62-103F1. Mr. Garreton will prepare and file a report containing the information required by Form 62-103F1 - Required Disclosure under the Early Warning Requirements in connection with the matters referred to in this press release. Once filed, a copy of the early warning report will be available under the Company's issuer profile on SEDAR+ at Participation by Terraflos and Mr. Garreton in the Offering was considered a 'related party transaction' pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101"). The Company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with Terraflos' and Mr. Garreton's participation in the Offering in reliance of sections 5.5(b) and 5.7(1)(b) of MI 61-101. A material change report was filed in connection with the participation of Terraflos and Mr. Garreton in the Offering less than 21 days in advance of the closing of the Offering, which the Company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the Offering in an expeditious manner. About Blueberries Medical Corp. Blueberries is a Latin American licensed producer of premium quality cannabis derivatives with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries' combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products. Additional information about the Company is available at For more information, please contact: Gustavo Gutiérrez, Country Manager, Colombia Operations Tel: +57 317 667 4812 Thomas Rodriguez Prats, Chief Financial Officer [email protected] Tel: +57 311 617 4246 Cautionary Note Regarding Forward-Looking Information This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the use of proceeds from the Offering, commencement of commercial production of CBD-dominant oils and products, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones is contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company's cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained under the heading 'Risk Factors' in the Company's Listing Statement dated January 31, 2019 and such other risk factors included in the management's discussion and analysis of the Corporation for the year ended December 31, 2023, each filed on its issuer profile on SEDAR+ at
Yahoo
07-03-2025
- Business
- Yahoo
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
TORONTO, March 07, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the 'Company' or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares ('Common Shares') at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the 'Offering'). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2024. It is expected that the Offering will be led by Terraflos Inc. ('Terraflos'), a cannabis company with operations throughout Latin America that was founded, and is controlled, by Facundo Garreton, the Chairman, Chief Executive Officer and a director of Blueberries. Guillermo Rodriguez, a director of the Company, is also expected to participate in the Offering. Participation by Terraflos and Messrs. Garreton and Rodriguez (collectively, the 'Insiders') in the Offering will be considered a 'related party transaction' pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Company will be exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the participation of the Insiders in the Offering in reliance of sections 5.5(b) and 5.7(1)(b) of MI 61-101. A material change report will be filed in connection with the participation by the Insiders in the Offering less than 21 days in advance of the closing of the Offering, which the Company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the Offering in an expeditious manner. About Blueberries Medical Corp. Blueberries is a Latin American licensed producer of premium quality cannabis derivatives with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries' combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products. Additional information about the Company is available at For more information, please contact: Gustavo Gutiérrez, Country Manager, Colombia Operationsggutierrez@ +57 317 667 4812 Thomas Rodriguez Prats, Chief Financial Officertrodriguez@ Tel: +57 311 617 4246 Cautionary Note Regarding Forward-Looking Information This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the use of proceeds from the Offering, commencement of commercial production of CBD-dominant oils and products, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones is contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company's cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's Listing Statement dated January 31, 2019 and such other risk factors included in the management's discussion and analysis of the Corporation for the year ended December 31, 2023, each filed on its issuer profile on SEDAR+ at No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained in to access your portfolio
